What one share of NeuroSense Therapeutics holds
Enterprise, or SME, status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe
NeuroSense Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.44 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.30 |
| Cash and investments | $0.01 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.65 | $0.00 | −$0.25 | — | — |
| 2022 | — | −$0.91 | $0.01 | −$0.67 | — | $0.51 |
| 2023 | — | −$0.74 | $0.00 | −$0.61 | — | −$0.11 |
| 2024 | — | −$0.55 | $0.00 | −$0.55 | — | $0.11 |
| 2025 | — | −$0.44 | $0.00 | −$0.30 | — | −$0.05 |
Common questions about NeuroSense Therapeutics
How much does one share of NeuroSense Therapeutics earn?
Over its latest fiscal year, NeuroSense Therapeutics lost $0.44 for each share.
Does NeuroSense Therapeutics pay a dividend?
NeuroSense Therapeutics didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is NeuroSense Therapeutics’s book value per share?
NeuroSense Therapeutics’s book value is negative (−$0.05 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of December 31, 2025.
How much cash and debt does each share of NeuroSense Therapeutics have?
Each share of NeuroSense Therapeutics has $0.01 of cash and investments, as of December 31, 2025.
What is NeuroSense Therapeutics’s free cash flow per share?
−$0.30 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has NeuroSense Therapeutics bought back shares?
NeuroSense Therapeutics’s share count rose about 310% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.